Lim Jong-yoon, Chairman of Kori Group, has been appointed as the Managing Director of Beijing Hanmi Pharmaceutical Co., Ltd., a subsidiary of Hanmi Pharmaceutical.
Beijing Hanmi recently held a board meeting composed of two directors from China's Hualun Group and three directors from Hanmi Pharmaceutical, where Chairman Lim Jong-yoon was appointed as Managing Director. Additionally, Kwon Yong-nam as General Supervisor, Seo Young as Head of the Research and Development Center, and Lee Seon-ro, Kori Italy Representative, were newly appointed as directors, completing the registration process, the company announced on the 14th.
Kwon Yong-nam, Senior General Supervisor of Management Support at Beijing Hanmi Pharmaceutical, has been responsible for internal affairs such as finance and procurement since 2008, starting with Hanmi Healthcare in 2006.
Newly appointed Seo Young has been involved in research and development since 1989, starting as a researcher at the Chinese Academy of Medical Sciences, then working at Beijing Hanmi and Lunmeiking, and currently serves as Head of the Beijing Kori Science and Technology Research and Development Center.
Lee Seon-ro, Kori Italy Representative, joined Hanmi Pharmaceutical’s sales department in 1999 and has served as head of the planning department and management planning office at Beijing Hanmi.
Beijing Hanmi was established in 1996 as a joint venture between Hanmi Pharmaceutical and the Chinese state-owned enterprise Hualun Zajuyak Industry. Chairman Lim Jong-yoon took on the role of Managing Director of Beijing Hanmi in 2005.
Beijing Hanmi Pharmaceutical’s sales, which were in the 10 billion KRW range in 2004, reached 385.6 billion KRW last year, recording over 300 billion KRW in sales for three consecutive years.
At this point, as the management dispute of Hanmi Pharmaceutical, which has been ongoing for over a year, is nearing resolution, this development rekindles expectations for the successful DNA of Beijing Hanmi.
Lim Jong-yoon, Managing Director of Beijing Hanmi, has completed clinical development and approval for about 20 pharmaceutical products based on thoroughly localized infrastructure in China’s pharmaceutical market, the world’s second largest at 225 trillion KRW (China’s drug approval process takes an average of 5 to 7 years per product). He has also developed four market-leading products, including the digestive aid Mamiai.
In particular, he has experience growing profit margins well beyond 20%.
There is growing anticipation that the re-acceleration of Beijing Hanmi, equipped with successful DNA, experience, and potential, could expedite the reconstruction of K-Bio under the Hanmi Pharmaceutical Group.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
